Satralizumab
Satralizumab is a humanized monoclonal antibody that targets IL-6R. Satralizumab prevents dTAA formation and progression in rattus norvegicus. Satralizumab can be used for neuromyelitis optica spectrum disorder (NMOSD) and descending thoracic aorta aneurysm (dTAA) research[1][2][3].
Product Specifications
CAS Number
1535963-91-7
Product Name Alternative
RG-6168; SA-237
UNSPSC
12352203
Hazard Statement
H302, H315, H319, H335
Target
Interleukin Related
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/satralizumab.html
Purity
99.82
Solubility
H2O
Smiles
[Satralizumab]
Molecular Weight
(144.5 kDa)
Precautions
H302, H315, H319, H335
References & Citations
[1]Heydari AH, et al. Satralizumab, Novel Interleukine-6 Inhibitor for Preventing Descending Thoracic Aorta Aneurysm Development. Cardiovasc Drugs Ther. 2021 Nov 26. |[2]Duchow A, et al. Satralizumab in the treatment of neuromyelitis optica spectrum disorder. Neurodegener Dis Manag. 2021 Feb;11 (1) :49-59.|[3]Bennett JL, et al. Long-Term Efficacy and Safety of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disorder From the SAkuraMoon Open-Label Extension Study. Neurol Neuroimmunol Neuroinflamm. 2025 Sep;12 (5) :e200450.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Launched
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNUB1060-100 1x 100 µL
Chromogranin A (CGA414 + CGA/777 + CGA/798), 0.2mg/mL
Sign In for Pricing
View Details 
BNC942200-500 1x 500 µL
Cytokeratin 7 (Glandular and Transitional Epithelial Marker) (KRT7/2200), CF594 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 